Publications by authors named "Xue-Lu Zhu"
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
J Hematol Oncol
October 2022
Article Synopsis
- - The study focused on treating high-risk acute promyelocytic leukemia (APL) using oral arsenic and all-trans retinoic acid (ATRA) without chemotherapy, aiming for effective outpatient care.
- - In a phase 2 clinical trial with 54 participants, the 2-year disease-free survival (DFS) rate was 94% and overall survival (OS) was 100%, with complete molecular remission achieved by all patients after consolidation.
- - Adverse events were mostly mild (grade 1-2), with only three cases of serious (grade 3) complications, indicating that the combination therapy was a safe and promising first-line treatment for high-risk APL.